Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5195 ARTÍCULOS , VIENDO DEL 3346 AL 3360

Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders

Silva AC, Lobo DD, Martins IM, Lopes SM, Henriques C, Duarte SP, Dodart JC, Nobre RJ, Pereira de Almeida L.

Brain. 2020 Feb 1;143(2):407-429. doi: 10.1093/brain/awz328.

A Systematic Review of Rehabilitation for Corticobulbar Symptoms in Adults with Huntington's Disease

Burnip E, Wallace E, Gozdzikowska K, Huckabee ML.

J Huntingtons Dis. 2020;9(1):1-12. doi: 10.3233/JHD-190384.

Could metformin be therapeutically useful in Huntington's disease?

Tang BL.

Rev Neurosci. 2020 Apr 28;31(3):297-317. doi: 10.1515/revneuro-2019-0072.

Sex differences in movement disorders

Meoni S, Macerollo A, Moro E.

Nat Rev Neurol. 2020 Feb;16(2):84-96. doi: 10.1038/s41582-019-0294-x. Epub 2020 Jan 3.

Clinical recommendations to guide physical therapy practice for Huntington disease

Quinn L, Kegelmeyer D, Kloos A, Rao AK, Busse M, Fritz NE.

Neurology. 2020 Feb 4;94(5):217-228. doi: 10.1212/WNL.0000000000008887. Epub 2020 Jan 6.

3-Nitrotyrosine: a versatile oxidative stress biomarker for major neurodegenerative diseases

Bandookwala M, Sengupta P.

Int J Neurosci. 2020 Oct;130(10):1047-1062. doi: 10.1080/00207454.2020.1713776. Epub 2020 Jan 21.

Advanced fluorescence imaging of in situ protein aggregation

Lu M, Kaminski CF, Schierle GSK.

Phys Biol. 2020 Feb 11;17(2):021001. doi: 10.1088/1478-3975/ab694e.

Role of Dietary Antioxidants in Neurodegenerative Diseases: Where are We Standing?

Bakir S, Catalkaya G, Ceylan FD, Khan H, Guldiken B, Capanoglu E, Kamal MA.

Curr Pharm Des. 2020;26(7):714-729. doi: 10.2174/1381612826666200107143619.

Armand Trousseau (1801-1867), a neurologist before neurology

Walusinski O.

Rev Neurol (Paris). 2020 Sep;176(7-8):531-542. doi: 10.1016/j.neurol.2019.12.002. Epub 2020 Jan 7.

Effectiveness of brexpiprazole in the treatment in a patient with Huntington's disease

Mimura Y, Funayama M, Oi H, Takata T, Takeuchi H, Mimura M.

Psychiatry Clin Neurosci. 2020 Apr;74(4):278-279. doi: 10.1111/pcn.12982. Epub 2020 Feb 7.

Excitotoxicity as a Target Against Neurodegenerative Processes

Binvignat O, Olloquequi J.

Curr Pharm Des. 2020;26(12):1251-1262. doi: 10.2174/1381612826666200113162641.

Recent Advances in the Treatment of Huntington's Disease: Targeting DNA and RNA

Shannon KM.

CNS Drugs. 2020 Mar;34(3):219-228. doi: 10.1007/s40263-019-00695-3.

The Renin-Angiotensin System in Huntington's Disease: Villain or Hero?

Machado TCG, Guatimosim C, Kangussu LM.

Protein Pept Lett. 2020;27(6):456-462. doi: 10.2174/0929866527666200110154523.

Mitophagy in Alzheimer's Disease and Other Age-Related Neurodegenerative Diseases

Cai Q, Jeong YY.

Cells. 2020 Jan 8;9(1):150. doi: 10.3390/cells9010150.

Therapeutic Advances for Huntington's Disease

Kumar A, Kumar V, Singh K, Kumar S, Kim YS, Lee YM, Kim JJ.

Brain Sci. 2020 Jan 12;10(1):43. doi: 10.3390/brainsci10010043.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias